The pandemic of SARSCov2 infection has created a challenge in health services worldwide. Some scales have been applied to evaluate the risk of intubation, such as the ROX and HACOR. The objective of this study is to compare the predictive capacity of the HACOR scale and the ROX index and define the optimal cut-off points. Study of diagnostic tests based on a retrospective cohort. Composite outcome was the proportion of patients that needed endotracheal intubation (ETI) or died of COVID19 pneumonia. Discrimination capacity was compared by the area under the curve of each of the two scales and the optimal cut-off point was determined using the Liu method. 245 patients were included, of which 140 (57%) required ETI and 152 (62%) had the composite end result of high-flow nasal cannula (HFNC) failure. The discrimination capacity was similar for the two scales with an area under receiver operating characteristic curve of 0.71 and 0.72 for the HACOR scale for the ROX index, respectively. The optimal cut-off point for the ROX index was 5.6 (sensitivity 62% specificity 65%), while the optimal cut-off point for the HACOR scale was 5.5 (sensitivity 66% specificity 65%). The HACOR scale and the ROX index have a moderate predictive capacity to predict failures to the HFNC strategy. They can be used in conjunction with other clinical variables to define which patients may require invasive mechanical ventilation.
BackgroundThe pandemic of SARSCov2 infection has created a challenge in health services worldwide. Some scales have been applied to evaluate the risk of intubation, such as the ROX and HACOR. The objective of this study is to compare the predictive capacity of the HACOR scale and the ROX index and define the optimal cut-off points.MethodsStudy of diagnostic tests based on a retrospective cohort. Composite outcome was the proportion of patients that needed orotracheal intubation or died of COVID19 pneumonia. Discrimination capacity was compared by the area under the curve of each of the two scales and the optimal cut-off point was determined using the Liu method.Results245 patients were included, of which 140 (57.14%) required OTI and 152 (62.04%) had the composite end result of HFNC failure. The discrimination capacity was similar for the two scales with an AUROC of 0.71 and 0.72 for the HACOR scale for the ROX index, respectively. The optimal cut-off point for the ROX index was 5.62 (sensitivity 62% specificity 65%), while the optimal cut-off point for the HACOR scale was 5.5 (sensitivity 66% specificity 65%).ConclusionsThe HACOR scale and the ROX index have a moderate predictive capacity to predict failures to the HFNC strategy. They can be used in conjunction with other clinical variables to define which patients may require invasive mechanical ventilation.
El consumo de sustancias psicoactivas es un problema de salud pública a nivel mundial. La cocaína ocupa un lugar importante, en cuanto a frecuencia de consumo, asociado a la necesidad de utilización de servicios médicos de urgencia por complicaciones derivadas de sobredosis e intoxicación con la exposición a la misma. Los efectos clínicos están plenamente caracterizados, pero dentro de estos no se identifica de manera clara y común la presencia de broncoespasmo. Entre los factores de riesgo para la generación del mismo encontramos exposición por vía inhalatoria y comorbilidad del paciente, entre las cuales el asma representa la gran mayoría de casos. Por esto se hace importante identificar dicha complicación asociada a contacto con esta sustancia, por lo que presentamos un caso en el cual el paciente desarrolla broncoespasmo severo con requerimiento de ventilación mecánica.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.